Cong Claire Xu Sells 3,494 Shares of I-Mab (NASDAQ:NBP) Stock

I-Mab (NASDAQ:NBP) SVP Cong Claire Xu sold 3,494 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $3.94, for a total transaction of $13,766.36. Following the completion of the transaction, the senior vice president directly owned 290,154 shares in the company, valued at approximately $1,143,206.76. This represents a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

I-Mab Trading Up 2.3%

NASDAQ:NBP opened at $1.75 on Thursday. The stock has a 50-day simple moving average of $2.24. The stock has a market capitalization of $202.39 million, a P/E ratio of -4.86 and a beta of 1.47. I-Mab has a twelve month low of $1.63 and a twelve month high of $6.79.

I-Mab (NASDAQ:NBP) last posted its quarterly earnings results on Wednesday, April 8th. The company reported ($0.30) earnings per share for the quarter. As a group, analysts expect that I-Mab will post -0.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on NBP shares. Wall Street Zen downgraded shares of I-Mab from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of I-Mab in a report on Wednesday, April 8th. Finally, Weiss Ratings raised shares of I-Mab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $9.00.

Institutional Investors Weigh In On I-Mab

A hedge fund recently bought a new stake in I-Mab stock. Brooklyn Investment Group bought a new position in shares of I-Mab (NASDAQ:NBP) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,715 shares of the company’s stock, valued at approximately $51,000. Institutional investors own 38.38% of the company’s stock.

About I-Mab

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.